SG11201802829YA - Early post-transfection isolation of cells (epic) for biologics production - Google Patents
Early post-transfection isolation of cells (epic) for biologics productionInfo
- Publication number
- SG11201802829YA SG11201802829YA SG11201802829YA SG11201802829YA SG11201802829YA SG 11201802829Y A SG11201802829Y A SG 11201802829YA SG 11201802829Y A SG11201802829Y A SG 11201802829YA SG 11201802829Y A SG11201802829Y A SG 11201802829YA SG 11201802829Y A SG11201802829Y A SG 11201802829YA
- Authority
- SG
- Singapore
- Prior art keywords
- epic
- cells
- early post
- biologics production
- transfection isolation
- Prior art date
Links
- 229960000074 biopharmaceutical Drugs 0.000 title 1
- 238000002955 isolation Methods 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000001890 transfection Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70592—CD52
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Food Science & Technology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Epoxy Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562239515P | 2015-10-09 | 2015-10-09 | |
| PCT/US2016/055918 WO2017062724A1 (fr) | 2015-10-09 | 2016-10-07 | Isolement post-transfection précoce de cellules (epic) pour la production de produits biologiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201802829YA true SG11201802829YA (en) | 2018-05-30 |
Family
ID=57211576
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201802829YA SG11201802829YA (en) | 2015-10-09 | 2016-10-07 | Early post-transfection isolation of cells (epic) for biologics production |
| SG10202111233SA SG10202111233SA (en) | 2015-10-09 | 2016-10-07 | Improved flare (flow cytometry attenuated reporter expression) technology for rapid bulk sorting |
| SG11201802823VA SG11201802823VA (en) | 2015-10-09 | 2016-10-07 | Improved flare (flow cytometry attenuated reporter expression) technology for rapid bulk sorting |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202111233SA SG10202111233SA (en) | 2015-10-09 | 2016-10-07 | Improved flare (flow cytometry attenuated reporter expression) technology for rapid bulk sorting |
| SG11201802823VA SG11201802823VA (en) | 2015-10-09 | 2016-10-07 | Improved flare (flow cytometry attenuated reporter expression) technology for rapid bulk sorting |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10317329B2 (fr) |
| EP (2) | EP3359665A2 (fr) |
| CN (3) | CN116660127A (fr) |
| AU (2) | AU2016335699A1 (fr) |
| CA (2) | CA3001238A1 (fr) |
| HK (1) | HK1259493A1 (fr) |
| IL (4) | IL258538B2 (fr) |
| MX (1) | MX2018004366A (fr) |
| SG (3) | SG11201802829YA (fr) |
| WO (2) | WO2017062722A2 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015191508A1 (fr) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Capsides chimériques |
| EP3215191A4 (fr) | 2014-11-05 | 2018-08-01 | Voyager Therapeutics, Inc. | Polynucléotides codant pour la dopa décarboxylase et destinés au traitement de la maladie de parkinson |
| CN107109407A (zh) | 2014-11-14 | 2017-08-29 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
| SG11201703419UA (en) | 2014-11-14 | 2017-05-30 | Voyager Therapeutics Inc | Modulatory polynucleotides |
| US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
| IL258538B2 (en) | 2015-10-09 | 2023-04-01 | Genzyme Corp | Early isolation after the infection of cells (epic) for the production of biological material |
| WO2017189959A1 (fr) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions pour le traitement de maladies |
| WO2017189964A2 (fr) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions pour le traitement de maladies |
| CA3024449A1 (fr) | 2016-05-18 | 2017-11-23 | Voyager Therapeutics, Inc. | Compositions et methodes de traitement de la maladie de huntington |
| CN110214187B (zh) | 2016-05-18 | 2024-01-30 | 沃雅戈治疗公司 | 调节性多核苷酸 |
| CL2016001661A1 (es) * | 2016-06-29 | 2017-03-03 | Univ Chile | Promotor hibrido de ß-actina (de cricetulus griseus) y citomegalovirus (cmv), con región rica en dinucleótidos, citosina-guanina, vectores, líneas celulares, procedimiento para producir proteínas recombinantes. |
| US11298041B2 (en) | 2016-08-30 | 2022-04-12 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
| AU2017341028B2 (en) | 2016-10-07 | 2023-12-21 | Genzyme Corporation | Early post-transfection isolation of cells (EPIC) for biologics production |
| EP3618839A4 (fr) | 2017-05-05 | 2021-06-09 | Voyager Therapeutics, Inc. | Compositions et méthodes de traitement de la sclérose latérale amyotrophique (sla) |
| SG11201909868YA (en) | 2017-05-05 | 2019-11-28 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| CN111132626B (zh) | 2017-07-17 | 2024-01-30 | 沃雅戈治疗公司 | 轨迹阵列引导系统 |
| WO2019079242A1 (fr) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | Traitement de la sclérose latérale amyotrophique (sla) |
| AU2018352236A1 (en) | 2017-10-16 | 2020-04-23 | The Curators Of The University Of Missouri | Treatment of amyotrophic lateral sclerosis (ALS) |
| CN116615655A (zh) | 2020-11-19 | 2023-08-18 | 建新公司 | 流式细胞术减弱报告物表达（flare）多种报告物系统及其使用方法 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4818700A (en) | 1985-10-25 | 1989-04-04 | Phillips Petroleum Company | Pichia pastoris argininosuccinate lyase gene and uses thereof |
| US4812405A (en) | 1986-02-18 | 1989-03-14 | Phillips Petroleum Company | Double auxotrophic mutants of Pichia pastoris and methods for preparation |
| US4937190A (en) | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
| US4929555A (en) | 1987-10-19 | 1990-05-29 | Phillips Petroleum Company | Pichia transformation |
| CA2063799A1 (fr) | 1989-07-24 | 1991-01-25 | Frank S. Genbauffe | Prevention de l'initiation interne |
| US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
| WO1994026087A2 (fr) | 1993-05-14 | 1994-11-24 | Connor Kim C O | Production de proteines de recombinaison, culture de cellules d'insectes et procede s'y rapportant |
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| US5955349A (en) | 1996-08-26 | 1999-09-21 | Zymogenetics, Inc. | Compositions and methods for producing heterologous polypeptides in Pichia methanolica |
| US5736383A (en) | 1996-08-26 | 1998-04-07 | Zymogenetics, Inc. | Preparation of Pichia methanolica auxotrophic mutants |
| WO1998037189A1 (fr) | 1997-02-25 | 1998-08-27 | Qbi Enterprises Ltd. | Sequences d'ires conferant une grande efficacite de traduction et vecteurs d'expression contenant la sequence |
| US7001733B1 (en) * | 1998-05-12 | 2006-02-21 | Rigel Pharmaceuticals, Inc. | Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement |
| US6258559B1 (en) | 1999-03-22 | 2001-07-10 | Zymogenetics, Inc. | Method for producing proteins in transformed Pichia |
| US20050005310A1 (en) * | 1999-07-12 | 2005-01-06 | Genentech, Inc. | Expression vectors and methods |
| CA2385102A1 (fr) * | 1999-07-12 | 2001-01-18 | Genentech, Inc. | Vecteurs d'expression et procedes |
| AU2001236624A1 (en) | 2000-02-02 | 2001-08-14 | Iconix Pharmaceuticals, Inc. | Rapid, parallel identification of cell lines |
| WO2002070710A1 (fr) | 2001-03-01 | 2002-09-12 | University Of California | Procede d'identification d'elements ires |
| DE10143238A1 (de) | 2001-09-04 | 2003-03-20 | Icon Genetics Ag | Identifizierung eukaryotischer interner Ribosomen-Eingangsstellen (IRES)-Elemente |
| DE10143237A1 (de) | 2001-09-04 | 2003-03-20 | Icon Genetics Ag | Herstellung künstlicher interner ribosomaler Eingangsstellenelemente (Ires-Elemente) |
| JP2005526517A (ja) | 2002-05-22 | 2005-09-08 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 分泌性ポリペプチドの検出 |
| US7119187B2 (en) | 2002-07-09 | 2006-10-10 | National Health Research Institutes | Internal ribosome entry site of the labial gene for protein expression |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| AU2003252111A1 (en) * | 2002-07-19 | 2004-02-09 | Diversa Corporation | Fluorescent proteins, nucleic acids encoding them and methods for making and using them |
| US7384744B2 (en) * | 2002-11-29 | 2008-06-10 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products |
| US7344886B2 (en) | 2002-11-29 | 2008-03-18 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product |
| WO2004060910A2 (fr) | 2002-12-16 | 2004-07-22 | Wayne State University | Peptides bioactifs et elements ires uniques provenant d'une proteolipoproteine de myeline plp/dm20 |
| WO2005000888A2 (fr) | 2003-06-24 | 2005-01-06 | Genzyme Corporation | Nouveaux promoteurs de l'actine beta et de la rps21, et leurs utilisations |
| US7776584B2 (en) | 2003-08-01 | 2010-08-17 | Genetix Limited | Animal cell colony picking apparatus and method |
| EP1749538A4 (fr) | 2004-03-31 | 2009-11-11 | Kirin Pharma Kk | Méthodes d'induction de différentiation de lymphocytes t réglementaires et prolifération de ceci avec agoniste de protéine d'ancrage gpi et composition médicinale de ceci |
| US7078179B2 (en) | 2004-05-04 | 2006-07-18 | Newlink Genetics Corporation | Selectable gene marker system based on expression of N-acetyllactosaminide 3-α galactosyltransferase |
| WO2006023248A2 (fr) * | 2004-07-28 | 2006-03-02 | The Trustees Of Columbia University In The City Of New York | Processus pour fabriquer et cristalliser des recepteurs couples aux proteines g |
| EP1809750B1 (fr) | 2004-11-08 | 2012-03-21 | ChromaGenics B.V. | Selection de cellules hotes exprimant une proteine a des niveaux eleves |
| US20060172382A1 (en) | 2004-11-08 | 2006-08-03 | Chromagenics B.V. | Selection of host cells expressing protein at high levels |
| WO2006063786A1 (fr) * | 2004-12-14 | 2006-06-22 | F.Hoffmann-La Roche Ag | MÉTHODE AMÉLIORÉE DE SÉLECTION DE TRANSFECTANTS ARNi |
| CA2648778A1 (fr) | 2006-04-10 | 2007-10-18 | The Regents Of The University Of California | Procede de culture de cellules sur des palettes amovibles pour expansionet analyse cellulaire subsequente |
| US20090239235A1 (en) | 2006-09-20 | 2009-09-24 | Demaria Christine | Facs- and Reporter Protein-Based System for High Throughput Development of Therapeutic Proteins |
| CN101778637B (zh) * | 2007-03-05 | 2013-05-29 | 新南创新私人有限公司 | 检测和调节肿瘤细胞对抗有丝分裂剂的敏感性的方法 |
| WO2012001073A2 (fr) * | 2010-07-01 | 2012-01-05 | Glaxo Group Limited | Procédé amélioré de sélection de lignées cellulaires à capacité de production élevée |
| EP2834259A4 (fr) * | 2012-04-02 | 2016-08-24 | Moderna Therapeutics Inc | Polynucléotides modifiés |
| EP2970956A1 (fr) * | 2013-03-11 | 2016-01-20 | Novartis AG | Procédé de recherche systématique de clones de cellules |
| IL258538B2 (en) | 2015-10-09 | 2023-04-01 | Genzyme Corp | Early isolation after the infection of cells (epic) for the production of biological material |
| AU2017341028B2 (en) | 2016-10-07 | 2023-12-21 | Genzyme Corporation | Early post-transfection isolation of cells (EPIC) for biologics production |
-
2016
- 2016-10-07 IL IL258538A patent/IL258538B2/en unknown
- 2016-10-07 SG SG11201802829YA patent/SG11201802829YA/en unknown
- 2016-10-07 IL IL297805A patent/IL297805A/en unknown
- 2016-10-07 CA CA3001238A patent/CA3001238A1/fr active Pending
- 2016-10-07 MX MX2018004366A patent/MX2018004366A/es unknown
- 2016-10-07 EP EP16788602.7A patent/EP3359665A2/fr active Pending
- 2016-10-07 IL IL258537A patent/IL258537B2/en unknown
- 2016-10-07 CN CN202310124801.8A patent/CN116660127A/zh active Pending
- 2016-10-07 SG SG10202111233SA patent/SG10202111233SA/en unknown
- 2016-10-07 EP EP16788603.5A patent/EP3359666A1/fr active Pending
- 2016-10-07 WO PCT/US2016/055915 patent/WO2017062722A2/fr active Application Filing
- 2016-10-07 SG SG11201802823VA patent/SG11201802823VA/en unknown
- 2016-10-07 CA CA3001364A patent/CA3001364A1/fr active Pending
- 2016-10-07 IL IL309289A patent/IL309289A/en unknown
- 2016-10-07 US US15/288,050 patent/US10317329B2/en active Active
- 2016-10-07 AU AU2016335699A patent/AU2016335699A1/en not_active Abandoned
- 2016-10-07 WO PCT/US2016/055918 patent/WO2017062724A1/fr active Application Filing
- 2016-10-07 US US15/288,036 patent/US11635363B2/en active Active
- 2016-10-07 CN CN201680072391.5A patent/CN108368505B/zh active Active
- 2016-10-07 CN CN201680071815.6A patent/CN108368504B/zh active Active
-
2019
- 2019-02-01 HK HK19101915.9A patent/HK1259493A1/zh unknown
- 2019-04-23 US US16/392,174 patent/US20200018682A1/en active Pending
-
2022
- 2022-11-25 AU AU2022275507A patent/AU2022275507A1/en active Pending
-
2023
- 2023-03-10 US US18/181,803 patent/US20230304913A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20170121734A1 (en) | 2017-05-04 |
| US10317329B2 (en) | 2019-06-11 |
| CN108368504B (zh) | 2022-07-19 |
| AU2022275507A1 (en) | 2023-02-02 |
| IL258537B2 (en) | 2024-05-01 |
| WO2017062722A3 (fr) | 2017-05-26 |
| AU2016335699A1 (en) | 2018-05-24 |
| CA3001238A1 (fr) | 2017-04-13 |
| EP3359665A2 (fr) | 2018-08-15 |
| SG11201802823VA (en) | 2018-05-30 |
| IL309289A (en) | 2024-02-01 |
| CA3001364A1 (fr) | 2017-04-13 |
| MX2018004366A (es) | 2018-08-01 |
| WO2017062724A1 (fr) | 2017-04-13 |
| CN108368505A (zh) | 2018-08-03 |
| US20170227441A1 (en) | 2017-08-10 |
| IL258538B2 (en) | 2023-04-01 |
| EP3359666A1 (fr) | 2018-08-15 |
| IL297805A (en) | 2022-12-01 |
| US11635363B2 (en) | 2023-04-25 |
| SG10202111233SA (en) | 2021-11-29 |
| IL258538B (en) | 2022-12-01 |
| IL258537B1 (en) | 2024-01-01 |
| CN108368505B (zh) | 2023-02-21 |
| US20230304913A1 (en) | 2023-09-28 |
| IL258538A (en) | 2018-05-31 |
| HK1259493A1 (zh) | 2019-11-29 |
| US20200018682A1 (en) | 2020-01-16 |
| CN108368504A (zh) | 2018-08-03 |
| WO2017062722A2 (fr) | 2017-04-13 |
| IL258537A (en) | 2018-05-31 |
| CN116660127A (zh) | 2023-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258538A (en) | Early isolation after the infection of cells (epic) for the production of biological material | |
| IL292504B1 (en) | Methods of preparing t cells for t cell therapy | |
| EP3368474A4 (fr) | Procédé électrochimique pour séparation de gaz | |
| EP3345990A4 (fr) | Système de production de cellules souches pluripotentes | |
| SG11201706636PA (en) | Single-cell nucleic acids for high-throughput studies | |
| EP3177904A4 (fr) | Isolement de cellules microfluidiques de plaquette cible | |
| EP3380655A4 (fr) | Système de fabrication de cellules à grande échelle | |
| EP3140425A4 (fr) | Procédés d'amplification linéaire du génome total d'une cellule unique | |
| HK1252635A1 (zh) | 製備原代細胞樣品的方法 | |
| PL3140392T3 (pl) | Produkcja białek heteromultimerycznych z wykorzystaniem komórek ssaków | |
| HK1251620A1 (zh) | 用於評估間充質幹細胞製劑的純度的方法 | |
| PL3119575T3 (pl) | Sposób wytwarzania izolacyjnego środnika | |
| GB2525950B (en) | Process for the production of dialkyl succinate | |
| GB201420428D0 (en) | Methods for nucleic acid isolation | |
| EP3233814A4 (fr) | Nouveau procédé de préparation de ranolazine | |
| GB2525949B (en) | Process for the production of dialkyl succinate | |
| EP3365920A4 (fr) | Procédé de fabrication de cellule bifaciale | |
| IL261999A (en) | Cell culture process | |
| EP3196304A4 (fr) | Procédé destiné à la production sécrétoire élevée améliorée de protéines | |
| GB201504459D0 (en) | Isolation of DNA | |
| SG10202103545PA (en) | Early post-transfection isolation of cells (epic) for biologics production | |
| PT3362405T (pt) | Processo e unidade de produção para a produção de metanol | |
| IL257814B (en) | A method for preparing praziquantel | |
| SG11201705095VA (en) | Process for the manufacture of solar cells | |
| GB201408753D0 (en) | Isolation of adipose derived cells |